【XWBOO Enterprise News】Recently, news showed that Wuhan Medline Digital Technology Co., Ltd, which is held by Hengrui Medicine, was established, with legal representative Sun He and a registered capital of RMB 10 million, and its business scope includes: pharmaceutical Internet information services; Internet information services; medical device Internet information services; second class value-added telecommunications business, etc.
In recent years, Hengrui Pharma has been continuously improving the level of production automation, intelligence and digitization while increasing the innovation capacity of new drug R&D and international development. Factory Demonstration Project.
At present, Hengrui Pharma has more than ten molecular companies, with more and more abundant product lines, a large number of suppliers and increasing complexity of management, which requires more and more digital supply chain and continues to deepen the combination with digitalization. It is reported that, in order to improve the overall operational efficiency of the supply chain to meet the new procurement needs of the group and molecular companies brought about by the current rapid development of the company, Hengrui Pharma also signed a contract with Yan Yun Technology in 2021, and the two sides reached a consensus on the implementation of the procurement management platform to jointly provide a more agile solution for the digital transformation of Hengrui Pharma's supply chain.
In fact, along with the development of cloud computing, 5G, Internet, big data and other technologies, a large number of pharmaceutical companies are now building their core competitiveness through digitalisation, big data and AI. In addition to the establishment of digital companies, the cooperation between pharmaceutical companies and digital enterprises and platforms has been increasing in recent years.
On 27 October, Epistar announced a research collaboration with Janssen Pharmaceuticals ("Janssen"), a subsidiary of Johnson & Johnson, to provide Janssen with design, screening, and synthesis services for new structural compounds. Under the agreement, Epistar will provide Janssen with small molecule active molecules with matching characteristics for specific targets. Cytech will deploy its comprehensive end-to-end platform - inclusive digital drug discovery and development, which includes proprietary cloud-based computing and advanced wet lab capabilities designed to shorten the Design-Make-Test-Analysis (DMTA) cycle.
On 24 October, Seritel also signed a collaboration agreement with Alpha Molecular for the co-development of new drugs. According to the agreement, the collaboration between Seritel and Alpha Molecular will combine Seritel's drug discovery, development and clinical translation capabilities with Alpha Molecular's biocomputing, AI and original biotechnology to further enhance the efficiency and success rate of new drug development and achieve a win-win situation for both parties in the field of new drug development.
In addition, China Resources Sanjiu has also mentioned in the research activities that the company has built a digital centre to transform its traditional business to build new business, and has achieved some initial results. At the same time, the company has also laid out smart manufacturing in its digital strategy, connecting the consumer side and the manufacturing side as well as the front-end traceability of Chinese medicine. It said it hopes to build a mature digital business model through 2-3 years of efforts.
......
Overall, among the various industrial players in the healthcare industry, the pharmaceutical industry, as a provider of treatment solutions, is moving from the primary stage of digital transformation to a more in-depth direction. In the future, as pharmaceutical companies continue to combine with digitalisation, digital technologies and platforms will help the various key players in the healthcare industry to achieve a comprehensive digital transformation.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone.
